argenx Q1 2026 EPS $5.52 beats by $0.07 as revenue $1.3B misses by about $20M on strong VYVGART
- VYVGART sales reached $1.3B in Q1 2026, up 63% year over year.
- argenx reported Q1 2026 profit of $366M, reflecting improved earnings versus the prior-year period.
- Company reiterates May 10, 2026 PDUFA date for seronegative gMG.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.